{
  "ticker": "CRSP",
  "company_name": "CRISPR Therapeutics",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT04035434",
      "title": "A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)",
      "status": "TERMINATED",
      "phase": "PHASE1, PHASE2",
      "condition": "B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL",
      "start_date": "2019-07-22",
      "completion_date": "2024-10-04",
      "enrollment": 0,
      "sponsor": "CRISPR Therapeutics AG"
    },
    {
      "nct_id": "NCT04244656",
      "title": "A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Multiple Myeloma",
      "start_date": "2020-01-22",
      "completion_date": "2024-01-04",
      "enrollment": 0,
      "sponsor": "CRISPR Therapeutics AG"
    },
    {
      "nct_id": "NCT05210530",
      "title": "An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Autoimmune Diseases, Immune System Diseases",
      "start_date": "2022-01-24",
      "completion_date": "2023-01-19",
      "enrollment": 0,
      "sponsor": "CRISPR Therapeutics AG"
    },
    {
      "nct_id": "NCT06492304",
      "title": "A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "T Cell Lymphoma, B Cell Lymphoma, Acute Myeloid Leukemia",
      "start_date": "2024-08-13",
      "completion_date": "2030-11",
      "enrollment": 0,
      "sponsor": "CRISPR Therapeutics"
    },
    {
      "nct_id": "NCT05795595",
      "title": "A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma, Malignant Pleural Mesothelioma",
      "start_date": "2023-03-13",
      "completion_date": "2025-09-18",
      "enrollment": 0,
      "sponsor": "CRISPR Therapeutics AG"
    },
    {
      "nct_id": "NCT06925542",
      "title": "A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis, Inflammatory Myopathy, Idiopathic, Myositis, Diffuse Cutaneous Systemic Sclerosis",
      "start_date": "2025-03-10",
      "completion_date": "2031-12-31",
      "enrollment": 0,
      "sponsor": "CRISPR Therapeutics"
    },
    {
      "nct_id": "NCT04502446",
      "title": "A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "T Cell Lymphoma",
      "start_date": "2020-07-31",
      "completion_date": "2024-08-30",
      "enrollment": 0,
      "sponsor": "CRISPR Therapeutics AG"
    },
    {
      "nct_id": "NCT06208878",
      "title": "A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies",
      "status": "ENROLLING_BY_INVITATION",
      "phase": "",
      "condition": "Hematologic Malignancy, Solid Malignancy",
      "start_date": "2023-11-22",
      "completion_date": "2038-08",
      "enrollment": 0,
      "sponsor": "CRISPR Therapeutics AG"
    },
    {
      "nct_id": "NCT03655678",
      "title": "A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent \u03b2-Thalassemia",
      "status": "COMPLETED",
      "phase": "PHASE2, PHASE3",
      "condition": "Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies",
      "start_date": "2018-09-14",
      "completion_date": "2025-11-13",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    },
    {
      "nct_id": "NCT05356195",
      "title": "Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent \u03b2-Thalassemia (TDT)",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies",
      "start_date": "2022-05-03",
      "completion_date": "2026-05-31",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    }
  ],
  "summary": {
    "total_trials": 16,
    "by_phase": {
      "PHASE1, PHASE2": 5,
      "PHASE1": 5,
      "": 1,
      "PHASE2, PHASE3": 2,
      "PHASE3": 3
    },
    "by_status": {
      "TERMINATED": 4,
      "COMPLETED": 4,
      "RECRUITING": 6,
      "ENROLLING_BY_INVITATION": 2
    },
    "active_trials": 8,
    "completed_trials": 4,
    "conditions": [
      "B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Large B-cell Lymphoma",
      "B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL",
      "Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies",
      "Beta-Thalassemia, Thalassemia, Sickle Cell Disease, Hematologic Diseases, Hemoglobinopathies, Genetic Diseases, Inborn, Sickle Cell Anemia",
      "Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma, Malignant Pleural Mesothelioma",
      "Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Autoimmune Diseases, Immune System Diseases",
      "Hematologic Malignancy, Solid Malignancy",
      "Multiple Myeloma",
      "Renal Cell Carcinoma",
      "SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis, Inflammatory Myopathy, Idiopathic, Myositis, Diffuse Cutaneous Systemic Sclerosis",
      "Sickle Cell Disease, Hematological Diseases, Hemoglobinopathies",
      "Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance, Hemoglobinopathies, Hematological Diseases",
      "T Cell Lymphoma",
      "T Cell Lymphoma, B Cell Lymphoma, Acute Myeloid Leukemia"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-05T17:58:28.366318",
    "search_query": "CRISPR Therapeutics",
    "url": "https://clinicaltrials.gov/search?term=CRISPR+Therapeutics"
  }
}